Objective: Several factors including disease condition and different procedures could alter pharmacokinetic profile of drugs in critically ill patients. For optimizing patient's outcome, changing in dosing regimen is necessary. Extracorporeal Membrane Oxygenation (ECMO) is one of the procedures which could change pharmacokinetic parameters.The aim of this review was to evaluate the effect of ECMO support on pharmacokinetic parameters and subsequently pharmacotherapy. Method: A systematic review was conducted by reviewing all papers found by searching following key words; extracorporeal membrane oxygenation, ECMO, pharmacokinetic and pharmacotherapy in bibliography database. Results: Different drug classes have been studied; mostly antibiotics. Almost all of the studies have been performed in neonates (as a case series). ECMO support is associated with altered pharmacokinetic parameters that may result in acute changes in plasma concentrations with potentially unpredictable pharmacological effect. Altreation in volume of distribution, protein binding, renal or hepatic clearance and sequestration of drugs by ECMO circuit may result in higher or lower doses requirement during ECMO. As yet, definite dosing guideline is not available. ECMO is extensively used recently for therapy and as a procedure affects pharmacokinetics profile along with other factors in critically ill patients. For optimizing the pharmacodynamic response and outcome of patients, drug regimen should be individualized through therapeutic drug monitoring whenever possible.
INTRODUCTION

Extracorporeal Membrane Oxygenation (ECMO)
is an advanced life support system for providing respiratory and cardiorespiratory support for patients of all ages who have failed conventional intensive care management. This technique was adopted from cardiopulmonary bypass used in open heart surgery and provides passive support of gas exchange and perfusion, thereby allowing implementation and optimisation of other forms of therapy to aid organ recovery (1) (2) (3) . Extracorporeal lung assist (ECLA), extracorporeal life support (ECLS), and extracorporeal CO2 removal (ECCOR) are other synonymes of ECMO. A variety of diagnosis, including Meconium Aspiration Syndrome (MAS), congenital diaphragmatic hernia (CDH), persistent pulmonary hypertension of the newborn (PPHN), respiratory distress syndrome, cardiac anomaly, sepsis or pneumonia are the reasons for performing ECMO in neonates (4) (5) (6) . Use of ECMO in adult patients both as a treatment for acute respiratory and cardiorespiratory failure or as a bridge to either cardiac transplantation or placement of a ventricular assist device is necessary (7) (8) (9) (10) (11) . In the cases of irreversible respiratory or cardiac failure and any contraindication for anticoagulation, ECMO should not be started. Advanced age, morbid obesity, neurologic dysfunction or poor pre-existing functional status are other exclusion conditions (7; 12) . There are two types of ECMO-Venoarterial (VA) and Venovenous (VV). Generally during ECMO, a large volume of blood is extracted from the venous system (large central vein) and circulated outside the body by a mechanical pump (centrifugal or roller), where the blood passes through an oxygenator and heat exchanger. In the oxygenator, hemoglobin becomes fully saturated with oxygen, while CO 2 is removed. Finally the blood is returned into the native vascular system (venous system near the right atrium in VV and arterial system in the aorta in VA ECMO) (3; 13) . In VV ECMO the circulation is powered entirely by native cardiac function, so it just provides support for respiratory failure, but in VA ECMO blood bypassing the heart and lungs, so it can be used for both respiratory and cardiac failures. Avoiding arterial cannulation and maintaining pulsatile blood flow to the patient are other advantages of VV ECMO (2; 11; 13). Depending on diagnosis and age group, ECMO increase survival rate to 50-95% in comparison with conventional treatment such as mechanical ventilation with high inspired fractional oxygen or instillation of surfactant. Survival rate for children requiring ECMO for respiratory support is 63%, for children needing cardiac support is 55% and for adults it is nearly 50 % (14-17).
Critically ill patient's exihibit a range of organ dysfunctions and often require therapeutic support with a variaty of procedures including mechanical ventilation and renal replacement therapy. These procedures along with underlying pathophysiological process result in changes in major pharmacokinetic parameters such as volume of distribution (Vd) and clearance (CL) in critically ill patients (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Several aspects of ECMO (as a procedure in ICU) such as sequestration of drug by ECMO circuit, increase in the volume of distribution, alteration in renal and hepatic blood flow, flow rate of the system and other factors change pharmacokinetic parameters of drugs (13; 29-34) . Of different drug classes some of them such as sedative (propofol) (35) or vasoprossors (norepinephrine) (36) could be easily titrated according to patient's response but for others especially antibiotics (cefepim, vancomycin) (37, 38) titration of dose based on patient response rate is not possible, thus applying pharmacokinetic principles in selection of drug and dosing regimen is crucial for optimization the pharmacodynamic response and outcome of patients. The aim of this study is to review the effect of ECMO support on pharmacokinetic parameters and optimal dosing regimen during ECMO.
METHODS
In order to provide enough databases about the subject, a systematic search utilizing Pubmed, Scopus, Googel Scholar and Embase database was carried out. The initial search terms were "extracorporeal membrane oxygenation", "ECMO", pharmacokinetic and pharmacotherapy, without narrowing or limiting search elements to find the most relevant literatures about the subject. References from each article were also evaluated for relevancy of inclusion in the study. All papers were reviewed to omit irrelevant or duplicate papers, and then their data were extracted into tables and summarized.
RESULTS AND DISCUSSION
As summarized in table 1, different drug classes have been studied in patients under ECMO. Almost all of these studies were performed in neonates and usually without control groups and on the basis of pharmacokinetic parameters such as volume of distribution, clearance and half life a dose or method for monitoring was recommended. Small sample size, differences in ECMO technique and equipment, complexity of patients with lack of uniform diagnosis, different methods for evaluation of kinetic were limitations of these studies which complicate clinical judgment. Also due to inadequate investigation, difinit recommendation for adults is not possible. Antibiotics, sedatives, analgesics, anticonvulsants are the most studied drugs in patients under ECMO ( Table 1) . Mixing of priming volume with the patient's own blood volume increase effective circulating volume and decrease in the total blood concentration is the immediate effect of this acute hemodilution (13; 29) . The pharmacological impact depend on the apparent Vd of the drugs, the degree of protein binding and the extent of equilibration between tissue and plasma concentrations on initiation of ECMO (13; 3 4; 39). Drugs with large Vd e.g. amiodarone (40) would be expected to show only a slight changes because drug back diffuse to plasma from large tissue reservoirs. In contrast, a drug with a small Vd such as gentamicin may be significantly affected and the resultant enlarged apparent Vd may affect the elimination rate of the drug. Depletion of the plasma protein such as albumin during acute hemodilution may affect plasma and tissue protein binding and plasma concentrations of drugs, but it is just a transient effect because transfusing blood and related products such as albumin will normalize the effects of hemodilution (39) . Changes in blood flow affect clearance of drugs during ECMO. VV ECMO result in pulsatile blood flow, whereas VA ECMO at high flow rates (>100ml/kg/min) may produce non-pulsatile flow. Non-pulsatile flow can alter perfusion of tissues, reduce capillary circulation and aerobic metabolism (41; 42). The kidneys interpret pulsless blood flow as hypotension and activate the renin-angiotensin system which result in reduced urine production and impaired sodium excretion. Regional blood flow changes in the liver can also affect drug clearance, in particular those drugs with a high extraction ratio e.g. propranolol (43) . Perfusion of tissues may also be altered as a result of activation of Systematic Inflammatory Response System (SIRS) releasing a variety of autonomic, endocrine and local cytokine that may affect not only tissue distribution of drugs but also clearance mechanism as well. The loss of drugs to the ECMO circuit (to tube or oxygenator) depend on the surface area in contact with the circulating fluid and extent of any physiochemical interactions between individual drugs and the different plastic components of the circuit (31, 44) . Based on studies for evaluation of drug sequestration during ECMO, significant sequestration of opioids (alfentanil, fentanyl, morphine), benzodiazepins (midazolam, diazepam, lorazepam), glyceryl nitrate and propofol, has been reported and it has also been described that ECMO circuit decrease levels of phenobarbital, heparin, vancomycin, gentamicin and phenytoin delivery (31; 44; 45) . Voriconazol, cefazolin and ampicillin are also sequestered during ECMO and therefore their therapeutic concentrations cannot be definite. Gentamicin is the most well studied drug in patients under ECMO (table 1). All of studies on gentamicin have been performed on neonates. None of studies had control groups and only pharmacokinetic parameters have been compared before and after stopping ECMO. Usually dose rate of 2.5 mg/kg every 12 hrs was administered for infants under ECMO, blood samples were collected after steady state (usually 3 days), pharmacokinetic parameters were evaluated and correlation between ages, weight, and serum creatinin had been evaluated. Cohn et al. (59) compared data for patients on ECMO and after discontinuation of ECMO. They reported significant increase in Vd and half life and decrease in clearance for patients on ECMO and a dose rates of about 25% lower than usual and longer dosing intervals for patients undergoing ECMO therapy. A retrospective study on 29 neonates receiving gentamicin during ECMO and a comparison of kinetic parameters with non-ECMO population showed that Vd (0.66± 0.2 L/kg) was median in ECMO groups in comparison with non-ECMO patients (0.58-0.75 L/kg) but half life increased significantly during ECMO (10.4 hour) (57) . According to results of all studies on gentamicin during ECMO (table 1), Vd was significantly higher and clearance was significantly lower in comparison with non-ECMO patients; because ECMO especially non-pulsatile method results in decrease of renal blood flow and Glomerulal Filtration Rate (GFR) and finally reduction in renal clearance. Gentamicin is a hydrophilic drug and increase in extracellular volume following ECMO result in an increase in Vd. To achieve therapeutic levels, a maintenance dose of 2.5 mg/kg every 18 hours was recommended in neonates without renal impairment. Vancomycin pharmacokinetic during ECMO has also been described. Buck et al. (54) conducted a retrospective study in 15 neonates who received vancomycin during ECMO and compared pharmacokinetic data with matched control. The most frequent regiments prescribed in both groups were 10 mg/kg every 8 hrs. The data was analysed using a one compartment model and showed a Vd of 0. 45 (53) reported no difference in kinetic profile. In all above studies the numbers of neonates were small (6-12 neonates). In one study conducted in adults, there were no significant differences in pharmacokinetic parameters between ECMO and non-ECMO groups (56) . Therefore due to differences in methods and populations, recommendation of a dosing regimen is not possible especially in adults. In other studies on antibiotic in ECMO patients, despite higher Vd in ECMO patients, standard dose of cefotaxime was recommended in neonates under ECMO (61) .Monitoring the level of voriconazol in patients under ECMO has been suggested because this drug is sequestered during ECMO. Caspofungin could be prescribed with the same dosage in ECMO patients (63) . Sedatives and analgesics are important classes of drugs which are extensively used in critically ill especially ECMO patients. For short term procedure fentanyl may be suitable for analgesia because this drug is extensively bind to ECMO circuit after 24 hrs and usually higher doses are required to achieve desired therapeutic effect during ECMO. In comparison, morphine concentrations were well preserved during ECMO in both crystalloid or blood primed circuit, therefore it is a preferred drug for prolonged period, However results of a study (47) has shown that morphine clearance which decreases (even to half) during ECMO leads to an increase in serum concentration and some neonates experience withdrawal syndrome after ECMO discontinuation, authors suggested that increase in hepatic blood flow might be a reason for decrease in clearance. On the other hand Jeroen et al. (66) concluded that morphine clearance was lower than non ECMO but increased rapidly and after 14 days was equal to the control group. Size and age are factors that significantly affect morphine clearance but pump flow or simultaneous drugs have no effect. Although initial morphine dosing may be guided by age and weight, but clearance and Vd change during prolonged ECMO which suggest that morphine therapy should be subsequently guided by clinical monitoring (46) (47) (48) . However morphine clearance In spite of considerable amount of pharmacokinetic studies during ECMO, because of small sample size, differences in methods and lack of control group, developing a guideline for dosing of drug during ECMO is difficult. Also because of potential changes in drug delivery during ECMO along with other changes in pharmacokinetic profile of critically ill patients, drug regiments should be individualized through therapeutic drug monitoring whenever possible, until further studies are carried out in this area.
